This product was successfully added to cart!
莫索尼定
品牌商品推荐
更多 >>-
牡荆素-4”-O-葡萄糖苷
-
灵仙新苷
-
异野漆树苷
-
1-溴-4-环己基苯
-
五水磷酸镁
-
Obolactone
商品详情
客户评价
| 中文名 |
莫索尼啶 |
|---|---|
| 英文名 |
4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine |
| 中文别名 |
莫索尼定,不带盐酸 | 4-氯-N-(4,5-二氢-1H-咪唑-2-基)-6-甲氧基-2-甲基-5-嘧啶胺 | 莫索尼定 |
| 英文别名 |
更多 |
| 描述 |
Moxonidine(BDF5895)是咪唑啉1型受体（I1-R）选择性激动剂，为降压剂。 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 相关类别 |
|
||||||||||||
| 溶解度 |
体外：
在DMSO中10mM
|
||||||||||||
| 储备液 |
|
||||||||||||
| 存储 |
|
||||||||||||
| 运输 |
室温;可能会有所不同 |
||||||||||||
| SMILES |
CC1=NC(OC)=C(NC2=NCCN2)C(Cl)=N1 |
||||||||||||
| 参考文献 |
|
||||||||||||
| 相关活性 小分子 |
1-(4-氨丁基)胍硫酸盐 | 尿囊素 | 盐酸莫索尼定 | CR4056 |
| 密度 | 1.5±0.1 g/cm3 |
|---|---|
| 沸点 | 364.7±52.0 °C at 760 mmHg |
| 熔点 | 40-43?°C(lit.) |
| 分子式 | C9H12ClN5O |
| 分子量 | 241.678 |
| 闪点 | 174.3±30.7 °C |
| 精确质量 | 241.073044 |
| PSA | 71.43000 |
| LogP | 0.84 |
| 外观性状 | 晶体 |
| 蒸汽压 | 0.0±0.8 mmHg at 25°C |
| 折射率 | 1.681 |
| 储存条件 | Desiccate at +4°C |
| 计算化学 |
1.疏水参数计算参考值（XlogP）:0.6 2.氢键供体数量:2 3.氢键受体数量:4 4.可旋转化学键数量:3 5.互变异构体数量:2 6.拓扑分子极性表面积71.4 7.重原子数量:16 8.表面电荷:0 9.复杂度:275 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
| 更多 |
1.性状：结晶 2.熔点（?C）：217-219℃(分解)。 |
| 危险品运输编码 | NONH for all modes of transport |
|---|---|
| WGK德国 | 3 |
| RTECS号 | UV6260290 |
| 莫索尼定上游产品? 5 | |
|---|---|
|
|
|
|
|
|
| 莫索尼定下游产品? 0 | |
![1-[1-((4,6-dichloro-2-methyl-pyrimidin-5-yl)imino)-ethyl]-imidazolidin-2-one结构式](https://www.chemsrc.com/caspic/129/438000-58-9.png)
方法1：5-氨基-4，6-二氯-2-甲基嘧啶和1-乙酰基-2-咪唑啉-2-酮反应，生成的产物和甲醇钠作用得莫索尼定。
方法2：5-氨基-4-氯-6-甲氧基-2-甲基嘧啶和硫氰酸铵及苯甲酰氯反应，得(I)。去苯甲酰基得(Ⅱ)，甲基化得(Ⅲ)，再和乙二胺作用得莫索尼定。
|
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr. Med. Res. Opin. 20(3) , 359-67, (2004)
Hypertension in combination with clinically overt diabetes mellitus is recognized as a particularly powerful combination of risk factors that greatly increases cardiovascular vulnerability. There is a...
|
|
|
Moxonidine: a review of safety and tolerability after seven years of clinical experience. J. Hypertens. 17 , S37-S39, (1999)
Centrally acting antihypertensive drugs, or sympatholytics, (reserpine, methyldopa and clonidine) have a long history of efficacy but are now little used in most countries. One of the most important r...
|
|
|
[The efficacy of antihypertension drugs and their combinations in the non-treated hypertension]. Med. Tr. Prom. Ekol. (5) , 7-11, (2013)
In case of non-treated hypertension several medications and their combinations were studied (captopril, and moxonidine as such, captopril + nifedipine, captopril + moxonidine). Moxonidine to be more e…
|
|
|
4-chloro-5-(imidazoline-2-ylamino)-6-methoxy-2-methylpyrimidine |
|
[3H]-Moxonidine |
|
4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine |
|
4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
|
Norcynt |
|
4-Chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine |
|
BE 5895 |
|
5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- |
|
Normoxocin |
|
Lomox |
|
4-chloro-N-(4,5-dihydro-1H9imidazol-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
|
Physiotens |
|
[14C]-Moxonidine |
|
4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine |
|
T6N CNJ B1 DO1 FG EM- BT5M CN BUTJ |
|
Nucynt |
|
Cynt |
|
Moxonidinum [Latin] |
|
Moxonidine |
|
T6N CNJ B1 DO1 FG ENU- BT5MYMTJ |
|
MFCD06795643 |
-
海量货源
1000+化工产品，覆盖300+小类
-
精品服务
我们以卓越的服务 已经有超过100家合作伙伴
-
使命
科技成就美好出行
-
核心价值观
成就客户、价值为纲、开放诚信 以奋斗者为本